Granulomatosis
Conditions
Keywords
Granulomatosis, sarcoidosis, Biological collection
Brief summary
The GRAMI-BIO study is a prospective single-centre cohort study to recruit 150 patients followed up in the the Bordeaux University Hospital. The total duration of the GRAMI-BIO study is ten years (five years of inclusion with five years of follow-up): Consecutive inclusion of patients meeting the definition of systemic granulomatosis. The main objective of this cohort is to describe to clinical progression of systemic granulomatosis and to collect blood fraction samples (serum bank, plasma bank, urine bank, DNA bank) from subjects participating in the cohort.
Detailed description
Systemic granulomatosis is a group of diseases whose common feature is the anatomopathological existence of giganto-cellular granulomas composed of macrophages, epithelial cells and CD4+ T lymphocytes. The exact cause of the development of these granulomas remains unknown, although numerous studies suggest the hypothesis of environmental factors (infectious, exposure to particles) and genetic susceptibility factors. The persistence of granulomas is deleterious, ultimately leading to local destruction and tissue damage resulting in fibrosis of neighbouring tissues. Granulomatosis is a heterogeneous group in terms of aetiology: schematically, either an aetiology is identified: infection, environmental factors (berylliosis, pneumoconiosis), iatrogenesis (drugs), neoplasia, immune deficiency; or granulomatosis is said to be idiopathic, the most common case, falling within the definition of systemic sarcoidosis. Therefore, with a view to future research work, it seems imperative to set up a biological bank of patients being monitored for systemic granulomatosis within the division. It is particularly important to identify genetic variants, circulating biomarkers associated with the onset, severity and response to treatment of these diseases. The main aim of the "GRAMI-BIO" study is to describe the clinical evolution of patients with systemic granulomatosis (sarcoidosis and other granulomatoses) followed at the Bordeaux University Hospital, and to collect samples from blood fractionation (serum bank, plasma bank, urine bank, DNA, RNA bank) to constitute a biobank.
Interventions
BIOLOGICALblood sample
30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
BIOLOGICALurine sample
10 ml
Sponsors
University Hospital, Bordeaux
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients aged 18 or over * Patients with systemic granulomatosis (diagnosis proven by anatomopathological sampling) at diagnosis. * Persons affiliated to or benefiting from a social security scheme. * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
Exclusion criteria
* Patients infected with human immunodeficiency virus (HIV), Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) * Pregnant or breast-feeding women * Patients already receiving specific treatment for systemic granulomatosis * Persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Describe the clinical progression of systemic granulomatosis | At baseline (Day 0) and 60 months after baseline |
Secondary
| Measure | Time frame |
|---|---|
| Identify predictive factors for the progression of the disease | At baseline (Day 0) and 60 months after baseline |
| Identify the management methods into patients with systemic granulomatosis | At baseline (Day 0) and 60 months after baseline |
| Identify predictive factors for response to treatments | At baseline (Day 0) and 60 months after baseline |
| Identify new clusters of the disease in a large population both clinically and biologically | At baseline (Day 0) and 60 months after baseline |
Countries
France
Contacts
CONTACTEmmanuel RIBEIRO, MD
CONTACTJean DELAUNE
PRINCIPAL_INVESTIGATOREmmanuel RIBEIRO, MD
University Hospital, Bordeaux
Outcome results
None listed